Sugi Predict

Sugi Predict / Compounds / SCHEMBL1783438

SCHEMBL1783438

SCHEMBL1783438

CCCc1[nH]c(C(=O)OCC)c(C)c1C=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ POLB P06746 1/20 0.54
▸ HPGD P15428 3/20 0.51
▸ HTT P42858 2/20 0.51
▸ MAPK1 P28482 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ TSHR P16473 3/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ ALOX12 P18054 1/20 0.47
▸ MAPT P10636 1/20 0.46
▸ LMNA P02545 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ ALOX15 P16050 1/20 0.44
▸ RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22279332 0.85 HPGD (0.49) ALDH1A1KMT2APOLBHPGDHTT
SCHEMBL12607018 0.83 CYP1A2 (0.42) ALDH1A1KMT2APOLBHPGDHTT
SCHEMBL18891359 0.83 LMNA (0.43) ALDH1A1KMT2APOLBHPGDHTT
SCHEMBL18891360 0.81 SMN1; SMN2 (0.35) ALDH1A1KMT2APOLBHPGDHTT
SCHEMBL1801531 0.81 HPGD (0.69) ALDH1A1KMT2APOLBHPGDHTT
SCHEMBL11648815 0.80 HPGD (0.65) ALDH1A1KMT2APOLBHPGDHTT
SCHEMBL11649891 0.80 NPSR1 (0.61) ALDH1A1KMT2APOLBHPGDHTT
SCHEMBL11651601 0.78 CYP1A2 (0.57) ALDH1A1KMT2APOLBHPGDHTT
SCHEMBL11647718 0.76 CYP1A2 (0.50) ALDH1A1KMT2APOLBHPGDHTT
SCHEMBL11650706 0.75 NPSR1 (0.59) ALDH1A1KMT2APOLBHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320216-A1 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2025-10-16 — — US disclosed
US-12351585-B2 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof TOPADUR PHARMA AG (CH) 2025-07-08 — — US disclosed
US-20240343730-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2024-10-17 — — US disclosed
US-11897890-B2 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof TOPADUR PHARMA AG (CH) 2024-02-13 — — US disclosed
US-20220169655-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2022-06-02 — — US disclosed
US-20220169655-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2022-06-02 — — US disclosed
EP-3377495-B1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1-F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2022-03-16 — — EP disclosed
US-11242347-B2 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof TOPADUR PHARMA AG (CH) 2022-02-08 — — US disclosed
US-11242347-B2 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof TOPADUR PHARMA AG (CH) 2022-02-08 — — US disclosed
CN-108290896-B 2-phenyl-3, 4-dihydropyrrolo [2,1-F ] [1,2,4] triazinone derivatives and uses thereof 托帕杜制药公司 2021-09-28 — — CN disclosed
US-20200239478-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2020-07-30 — — US disclosed
US-10570137-B2 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof TOPADUR PHARMA AG (CH) 2020-02-25 — — US disclosed
US-10570137-B2 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof TOPADUR PHARMA AG (CH) 2020-02-25 — — US disclosed
US-20180312513-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2018-11-01 — — US disclosed
EP-3377495-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F][1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF Topadur Pharma AG (CH) 2018-09-26 — — EP disclosed
WO-2017085056-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2017-05-26 — — WO disclosed
US-8273901-B2 Process of forming a pyrrole compound Nanyang Technical University (SG) 2012-09-25 — — US disclosed
US-8273901-B2 Process of forming a pyrrole compound Nanyang Technical University (SG) 2012-09-25 — — US disclosed
US-20110124881-A1 PROCESS OF FORMING A PYRROLE COMPOUND NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2011-05-26 — — US disclosed
US-20110124881-A1 PROCESS OF FORMING A PYRROLE COMPOUND NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2011-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124881-A1 PROCESS OF FORMING A PYRROLE COMPOUND OXER1, OGDH, OPRD1 ALDH1A1 67/4885KMT2A 1604/4885POLB 2232/4885
US-20220169655-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF PDE7A, GNAO1, PDE3A ALDH1A1 759/4885KMT2A 3833/4885POLB 1262/4885
US-11242347-B2 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof PDE7A, PDE3A, CHRM3 ALDH1A1 809/4885KMT2A 4114/4885POLB 1106/4885
US-20240343730-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF PDE7A, PDE3A, GNAO1 ALDH1A1 623/4885KMT2A 3847/4885POLB 1256/4885
US-20250320216-A1 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF PDE7A, PDE3A, PDE3B ALDH1A1 702/4885KMT2A 4063/4885POLB 1470/4885
US-20180312513-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF PDE7A, GNAO1, PDE3A ALDH1A1 759/4885KMT2A 3833/4885POLB 1262/4885
US-10570137-B2 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof PDE7A, GNAO1, PDE3A ALDH1A1 759/4885KMT2A 3833/4885POLB 1262/4885
US-20200239478-A1 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF PDE7A, GNAO1, PDE3A ALDH1A1 759/4885KMT2A 3833/4885POLB 1262/4885
US-11897890-B2 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof PDE7A, GNAO1, PDE3A ALDH1A1 759/4885KMT2A 3833/4885POLB 1262/4885
US-12351585-B2 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof PDE7A, PDE3A, GNAO1 ALDH1A1 623/4885KMT2A 3847/4885POLB 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.